E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the mean serum concentrations of Insulin-Like Growth Factor-1 (IGF-1) and Growth Hormone (GH) in acromegalic patients treated with C2L-OCT-01 PR, 30 mg administered IM every 42 days for 84 days, or Sandostatin LAR® 30 mg administered IM every 28 days for 84 days |
|
E.2.2 | Secondary objectives of the trial |
- To compare the octreotide plasma concentrations in both groups. - To compare the clinical efficacy of both products based on changes in signs and symptoms of acromegaly, acromegaly severity index, patient’s health status. - To evaluate and compare the clinical and biological safety profile of both products
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Main Inclusion Criteria •Male or Female •Age ≥18 years ≤ 65 years •Diagnostic of active acromegaly based on accepted criteria. •If treated with a long acting somatostatin analogue, the treatment has been unchanged for a minimum of 12 weeks. •Having IGF-1 serum levels at entry with the following characteristics: - If the patient is already treated with Sandostatin LAR® 30 mg: IGF-1 at entry must be normal (less than 10 % above the upper limit of reference range, based on gender and age). - If the patient is treated with Sandostatin LAR® 20 mg: any value. - If the patient is treated with Sandostatin® immediate release or dopamine agonists*, or not treated: value of IGF-1 at entry must be above 10% of upper limit of reference range, based on gender and age. * (A wash out period of a minimum of seven days of dopamine agonists will be needed prior to test drug administration). •Having the ability to understand the requirements of the study, provide written informed consent to participate in this study and agree to abide by the study restrictions
|
|
E.4 | Principal exclusion criteria |
•Female patients of childbearing potential age who are not taking adequate contraception. •Pregnant or lactating female patients. •Treated with a GH receptor antagonist (pegvisomant) within 12 weeks prior to admission into the study. •Had undergone pituitary surgery within six months or radiotherapy within two years prior to admission into the study. •Presenting any contra-indication to Sandostatin LAR® treatment, namely hypersensitivity to octreotide or any components of the formulation. •Having other conditions that could result in altered GH or IGF-1 levels (severe hepatic or renal disease, anorexia nervosa, Laron’s syndrome, treatment with levodopa or narcotic analgesics, heroin abuse). •Presenting signs and symptoms potentially related to a tumor compression of the optical chiasm (unless there are stable sequelae remaining after surgery). •Known or suspected contra-indication, allergy, hypersensitivity to the test article ingredients or any allowed study medication. •Presenting clinically significant laboratory abnormalities. •Having received an investigational drug or participated in a clinical trial within 30 days of study entry. •Presenting clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy (with the exception of diabetes mellitus related to acromegaly). •Presenting any grossly out-of-range laboratory value (other than noted in Exclusion Criteria, Protocol Section 5.2.2 item #9) unless approved by the Sponsor’s Medical Monitor or by the Principal Consultant. •Had undergone any surgery within four weeks of study entry unless approved by the Sponsor’s Medical Monitor or by the Principal Consultant. •Presenting an abnormal 12-lead electrocardiogram (ECG) which, in the opinion of the Investigator, is clinically serious, unstable or significant. •Presenting with symptomatic biliary lithiasis. Presenting any other conditions or prior therapy which, in the opinion of the Investigator, would make the patient unsuitable for this study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Efficacy Outcome Measures: •Percent changes in IGF-1 serum concentrations at Day 84, when compared to Baseline. •Percent changes in GH serum concentrations (mean of three values at one hour interval at each time point) at Day 84, when compared to Baseline.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 3 |